Skip to main content
OpenTrials
Completed

NCT Number: NCT07425509

Evaluation of a Stannous Fluoride Dentifrice for Control of Oral Malodor

This single-center, randomized, double-blind, two-treatment crossover clinical study evaluated the safety and efficacy of a stannous fluoride-containing dentifrice compared with a sodium fluoride control dentifrice for the control of intrinsic oral malodor. Adult subjects brushed twice daily with each product during separate treatment periods following standardized wash-out periods. Oral malodor was assessed using trained organoleptic judges applying a validated Odor Intensity (OI) scale at baseline and multiple post-treatment time points.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Salus Research, Inc.

Fort Wayne, Indiana, 46825, United States

About this study

This four-week, randomized, double-blind crossover study enrolled generally healthy adult subjects with qualifying intrinsic oral malodor. Following screening and an acclimation wash-out period using an ADA-accepted sodium fluoride dentifrice, subjects were randomized to one of two treatment sequences: TheraBreath® Healthy Gums Toothpaste or Crest® Cavity Protection Toothpaste. Each treatment period included supervised and at-home twice-daily brushing without tongue brushing or use of non-study oral hygiene products. Oral malodor was evaluated at baseline, 12-hour overnight, and 4- and 8-hour post-brushing time points on Day 1 and Day 7 using standardized organoleptic assessments performed by three trained judges. Safety was monitored through oral examinations and subject interviews. Treatment comparisons were analyzed using ANCOVA models appropriate for crossover designs.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adults ≥18 years of age in good general health
  • Baseline odor intensity score ≥2 after approximately 12 hours of oral hygiene abstention
  • Intra-oral source of oral malodor
  • At least 18 natural teeth
  • Willing to comply with oral hygiene, dietary, and behavioral restrictions
  • Able to provide informed consent

Exclusion criteria

  • Allergy to oral hygiene products
  • Pregnant or nursing
  • Serious medical conditions affecting oral malodor
  • Recent antibiotic or anti-inflammatory medication use
  • Smoker or user of smokeless tobacco
  • Advanced periodontal disease, frank caries, or significant oral pathology
  • Participation in another oral care study within 30 days

Treatment and study plan

Sodium Fluoride Dentifrice

Drug

Comparator toothpaste (0.243% NaF)

Stannous Fluoride Toothpaste (SnF)

Drug

Test toothpaste (0.454% SnF)

Primary outcomes

  1. Change in Odor Intensity Score (OI

    Time frame: Baseline to 12-hour overnight assessment after 7 days of product use

Secondary outcomes

  1. Change in Odor Intensity Score at Day 1

    Time frame: Mean change in Odor Intensity Scores from baseline to Day 1 overnight assessment.

Other outcomes

  1. Daytime Odor Intensity Scores

    Time frame: 4 and 8 hours post-brushing on Day 1 and Day

Sponsors and collaborators

Lead sponsor

Church & Dwight Company, Inc.

Industry

Registry information

Official study title

A Randomized Crossover Clinical Evaluation of a Stannous Fluoride Containing Dentifrice on Oral Malodor

Important dates

Study start
2024
Primary completion
2024
Study completion
2024
First posted
Feb 23, 2026
Registry last updated
Feb 23, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.